Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company's products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company's new molecular entities (NMEs), which are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Ixekizumab, Necitumumab, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In February 2012, the Company acquired ChemGen Corp. On July 7, 2011, it acquired the animal health business of Janssen, a Johnson & Johnson company.
|Headquarters||LILLY CORPORATE CENTER|
INDIANAPOLIS, IN, United States 46285
|Acting Chairperson of the Board, Lead Independent Director||Ellen Marram|
|Acting Chief Executive Officer, Chief Financial Officer, Executive Vice President - Global Services||Derica Rice|
|President - Manufacturing Operations||Maria Crowe|
|Executive Vice President - Science and Technology, President - Lilly Research Laboratories||Jan Lundberg|
|Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer||Melissa Barnes|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||1.1B||Book Value||$12.91|
|Annual Dividend Rate||$1.96||Price/Sales (TTM)||2.8|
|Ex-Div Date||5/14/13||P/Cash Flow (TTM)||10.4x|
|Pay Date||8/14/13||Operating Margin||26.65%|
*GAAP = prior to non-GAAP analyst adjusted earnings.